Patents by Inventor Michael Wetter
Michael Wetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944675Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.Type: GrantFiled: October 2, 2020Date of Patent: April 2, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Fabiana Fernandez, Michael Kowarik, Michael Wacker, Michael Wetter
-
Patent number: 11878375Abstract: A clamping apparatus for clamping shaped parts which are welded along a welding contour by irradiation with a laser beam, includes a first clamping plate used as a holder for a first shaped part, a second clamping plate which is designed to apply a clamping force to the first shaped part and a second shaped part arranged thereon, an outer clamping jaw including a recess and an inner clamping jaw arranged in the recess, which together form the second clamping plate, a passage gap for the laser beam formed in sections between the outer clamping jaw and the inner clamping jaw, and one or more fastening elements which connect the outer clamping jaw with the inner clamping jaw in sections and which bridge the passage gap; and further includes a mirror element arranged such that the laser beam is reflected onto a section of the welding contour.Type: GrantFiled: February 4, 2019Date of Patent: January 23, 2024Assignee: EVOSYS LASER GMBHInventors: Michael Wetter, Andreas Kraus, Kreshnik Ahmeti
-
Patent number: 10973901Abstract: Provided herein are prokaryotic cells proficient to produce glycoconjugates in vivo, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.Type: GrantFiled: July 13, 2018Date of Patent: April 13, 2021Assignee: GlaxoSmithKline Biologicals SAInventors: Michael Wacker, Michael Kowarik, Michael Wetter, Amirreza Faridmoayer
-
Publication number: 20210085772Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.Type: ApplicationFiled: October 2, 2020Publication date: March 25, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Fabiana FERNANDEZ, Michael KOWARIK, Michael WACKER, Michael WETTER
-
Publication number: 20210053163Abstract: A clamping apparatus for clamping shaped parts which may be welded along a welding contour by irradiation with a laser beam, includes a first clamping plate used as a holder for a first shaped part, a second clamping plate which is designed to apply a clamping force to the first shaped part and a second shaped part arranged thereon, an outer clamping jaw including a recess and an inner clamping jaw arranged in the recess, which together form the second clamping plate, a passage gap for a laser beam formed in sections between the outer clamping jaw and the inner clamping jaw, and one or more fastening elements which connect the outer clamping jaw with the inner clamping jaw in sections and which bridge the passage gap. The clamping apparatus includes a mirror element arranged such that a laser beam is reflected onto a section of the welding contour.Type: ApplicationFiled: February 4, 2019Publication date: February 25, 2021Inventors: Michael WETTER, Andreas KRAUS, Kreshnik AHMETI
-
Patent number: 10835592Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.Type: GrantFiled: October 23, 2014Date of Patent: November 17, 2020Assignee: GlaxoSmithKline Biologicals SAInventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
-
Patent number: 10307473Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: GrantFiled: January 25, 2017Date of Patent: June 4, 2019Assignee: GlaxoSmithKline Biologicals SAInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Publication number: 20190076517Abstract: Provided herein are prokaryotic cells proficient to produce glycoconjugates in vivo, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.Type: ApplicationFiled: July 13, 2018Publication date: March 14, 2019Applicant: GLYCOVAXYN AGInventors: Michael WACKER, Michael KOWARIK, Michael WETTER, Amirreza Faridmoayer
-
Patent number: 10195262Abstract: Provided herein are immunogenic compositions and vaccines for the treatment and prevention of Staphylococcus aureus infections. These immunogenic compositions and vaccines comprise combinations of bioconjugates capsular polysaccharides that are N-linked to one or more carrier proteins.Type: GrantFiled: December 3, 2014Date of Patent: February 5, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Publication number: 20170128559Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: ApplicationFiled: January 25, 2017Publication date: May 11, 2017Inventors: Michael WACKER, Michael Kowarik, Michael Wetter
-
Patent number: 9585950Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: GrantFiled: September 23, 2014Date of Patent: March 7, 2017Assignee: GLYCOVAXYN AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Publication number: 20160303213Abstract: Provided herein are immunogenic compositions and vaccines for the treatment and prevention of Staphylococcus aureus infections. These immunogenic compositions and vaccines comprise combinations of bioconjugates capsular polysaccharides that are N-linked to one or more carrier proteins.Type: ApplicationFiled: December 3, 2014Publication date: October 20, 2016Applicant: GLYCOVAXYN AGInventors: Michael WACKER, Michael KOWARIK, Michael WETTER
-
Publication number: 20150273043Abstract: Prokaryotic cells proficient to produce glycoconjugates in vivo are provided herein, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.Type: ApplicationFiled: November 7, 2013Publication date: October 1, 2015Inventors: Michael Wacker, Michael Kowarik, Michael Wetter, Amirreza Faridmoayer
-
Publication number: 20150238596Abstract: Provided herein is a bioconjugate comprising a carrier protein and a modified antigen of Escherichia coli, the O antigen 0121. Also provided herein are uses of said bioconjugate, such as the treatment and/or prevention of diseases caused by Salmonella enterica, including diseases caused by Salmonella enterica subspecies I serovar Typhi (S. typhi).Type: ApplicationFiled: September 10, 2013Publication date: August 27, 2015Applicant: GlycoVaxyn AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Publication number: 20150044254Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.Type: ApplicationFiled: October 23, 2014Publication date: February 12, 2015Applicant: GLYCOVAXYN AGInventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
-
Publication number: 20150010592Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: ApplicationFiled: September 23, 2014Publication date: January 8, 2015Applicant: GLYCOVAXYN AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Patent number: 8895014Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.Type: GrantFiled: February 19, 2009Date of Patent: November 25, 2014Assignee: Glycovaxyn AGInventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
-
Patent number: 8871491Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: GrantFiled: May 4, 2011Date of Patent: October 28, 2014Assignee: Glycovaxyn AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Publication number: 20110274720Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.Type: ApplicationFiled: May 4, 2011Publication date: November 10, 2011Applicant: GlycoVaxyn AGInventors: Michael Wacker, Michael Kowarik, Michael Wetter
-
Publication number: 20110097357Abstract: The present invention is directed to a bioconjugate vaccine, such as an 01-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X—N—Z—S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.Type: ApplicationFiled: February 19, 2009Publication date: April 28, 2011Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker